Reversine (A3760): Practical Guidance for Aurora Kinase Inhibition Workflows

What This Product Solves

Reversine (6-N-cyclohexyl-2-N-(4-morpholin-4-ylphenyl)-7H-purine-2,6-diamine) is a novel small molecule inhibitor that targets Aurora kinases A, B, and C, key regulators in mitotic progression and cell cycle control. By disrupting Aurora kinase signaling, Reversine enables precise modulation of mitotic checkpoint functions, making it a practical tool for investigating cancer cell proliferation inhibition and apoptosis induction in cancer cells. Its primary applications are in basic and translational research contexts such as cell cycle studies, mitotic checkpoint assays, and cervical cancer model investigations. Researchers use Reversine to dissect Aurora kinase–dependent pathways and assess the impact of targeted kinase inhibition in vitro and in vivo models. This compound is not intended for clinical or diagnostic use and should be deployed strictly in research workflows. For detailed mechanistic and translational perspectives, see related internal articles like "Reversine and the Mitotic Checkpoint: Strategic Insights", which offers foundational guidance on integrating Reversine into cell cycle studies, and "Reversine: A Precision Aurora Kinase Inhibitor for Cancer...", which presents workflow optimization strategies.

Protocol Parameters

• Solubility (DMSO) | ≥19.65 mg/mL | Stock preparation for in vitro assays | High solubility in DMSO enables preparation of concentrated stock solutions for accurate dosing in cell-based and biochemical assays | product_spec (APExBIO Reversine)
• Solubility (Ethanol with gentle warming/ultrasonication) | ≥6.69 mg/mL | Alternative solvent for specialized assay requirements | Enables use in systems where DMSO is undesirable or limited by cell line compatibility | product_spec (APExBIO Reversine)
• Storage temperature (solid form) | -20°C | Long-term compound stability | Maintains compound integrity and prevents degradation between experiments | product_spec (APExBIO Reversine)
• Working solution usage | Use promptly, avoid long-term storage | Application in cell-based/biochemical assays | Solutions are not stable for extended periods and should be freshly prepared to ensure reproducibility | workflow_recommendation
• Recommended application | In vitro and in vivo research only | Aurora kinase pathway interrogation in cancer models | Not validated for diagnostic or therapeutic use; restrict to basic/translational research | workflow_recommendation

Workflow Setup and QC Checklist

1. Stock Solution Preparation: Dissolve Reversine solid in DMSO to prepare high-concentration stock (≥19.65 mg/mL). For ethanol, use gentle warming and ultrasonication to reach ≥6.69 mg/mL.
2. Aliquoting: Dispense stock into single-use aliquots to minimize freeze-thaw cycles and compound degradation.
3. Storage: Store solid material at -20°C in a desiccated environment. Avoid repeated temperature fluctuations. Stocks should be kept at -20°C and thawed only when needed.
4. Solution Handling: Prepare working dilutions immediately before use. Discard any unused solutions rather than storing for later use.
5. Assay Design: Validate solvent compatibility (DMSO or ethanol) with the selected cell line or assay system. Include appropriate vehicle controls in each experiment.
6. Quality Control: Confirm compound identity and concentration using appropriate analytical methods (e.g., HPLC, UV-Vis) as part of initial lot qualification.
7. Documentation: Record batch numbers, preparation dates, and storage conditions for traceability.

Common Failure Modes and Fixes

• Precipitation in Solution: If Reversine precipitates after dilution, ensure solvent concentration is adequate and that mixing is thorough. Gentle warming or ultrasonication may help in ethanol; avoid exceeding recommended concentrations.
• Loss of Activity: Using solutions stored for extended periods may result in reduced efficacy. Always prepare fresh working solutions and minimize freeze-thaw cycles.
• Variable Cellular Responses: Solvent toxicity or batch-to-batch variability can confound results. Standardize vehicle concentrations across all wells and validate each new batch of compound with a pilot dose-response assay.
• Compound Insolubility in Aqueous Media: Reversine is insoluble in water. Attempting direct dilution into aqueous buffers leads to precipitation and assay interference—always use DMSO or ethanol as primary solvents.
• Incorrect Storage: Room temperature or repeated thawing can degrade compound integrity. Adhere strictly to -20°C storage and avoid prolonged exposure to ambient conditions.

Scope and Limitations

Reversine is validated for experimental use in cancer biology and cell cycle research, particularly for interrogating Aurora kinase signaling pathways and studying apoptosis induction in cancer cells. Its use is limited to in vitro and in vivo research models; it is not suitable for clinical, diagnostic, or therapeutic applications. Solubility is restricted to DMSO and ethanol, and solutions are not stable for long-term storage. Researchers should avoid using water or aqueous buffers as primary solvents. The efficacy and specificity of Reversine have been characterized for Aurora kinases A, B, and C, but off-target effects or broader kinase inhibition cannot be excluded without further characterization. For workflow-focused strategies and troubleshooting advice, refer to "Reversine (A3760): Practical Guidance for Reliable Mitotic Inhibition".

Conclusion

Reversine (A3760) from APExBIO is a practical Aurora kinase inhibitor for researchers requiring precise modulation of mitotic checkpoint pathways, particularly in cancer cell proliferation and apoptosis studies. By adhering to recommended solubility, storage, and handling parameters, users can maximize reproducibility and data integrity. For further details, consult the product page: Reversine.